Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Int J Pharm ; 656: 124086, 2024 May 10.
Article in English | MEDLINE | ID: mdl-38580074

ABSTRACT

Chronic myeloid leukemia is a life-threatening blood-cancer prevalent among children and adolescents. Research for innovative therapeutics combine drug-repurposing, phytotherapeutics and nanodrug-delivery. Ivermectin (Ivn) is a potent anthelmintic, repurposed for antileukemic-activity. However, Ivn exerts off-target toxicity. Methyl-dihydrojasmonate (MJ) is a phytochemical of known antileukemic potential. Herein, we developed for the first-time Ivn/MJ-coloaded nanostructured-lipid-carrier (Ivn@MJ-NLC) for leveraging the antileukemic-activity of the novel Ivn/MJ-combination while ameliorating possible adverse-effects. The developed Ivn@MJ-NLC possessed optimum-nanosize (97 ± 12.70 nm), PDI (0.33 ± 0.02), entrapment for Ivn (97.48 ± 1.48 %) and MJ (99.48 ± 0.57 %) and controlled-release of Ivn (83 % after 140 h) and MJ (80.98 ± 2.45 % after 48 h). In-vitro K562 studies verified Ivn@MJ-NLC prominent cytotoxicity (IC50 = 35.01 ± 2.23 µg/mL) with pronounced Ivn/MJ-synergism (combination-index = 0.59) at low-concentrations (5-10 µg/mL Ivn). Superior Ivn@MJ-NLC cytocompatibility was established on oral-epithelial-cells (OEC) with high OEC/K562 viability-ratio (1.49-1.85). The innovative Ivn@MJ-NLC enhanced K562-nuclear-fragmentation and afforded upregulation of caspase-3 and BAX (1.71 ± 0.07 and 1.45 ± 0.07-fold-increase, respectively) compared to control. Ex-vivo hemocompatibility and in-vivo-biocompatibility of parenteral-Ivn@MJ-NLC, compared to Ivn-solution, was verified via biochemical-blood analysis, histological and histomorphometric studies of liver and kidney tissues. Our findings highlight Ivn@MJ-NLC as an Ivn/MJ synergistic antileukemic platform, ameliorating possible adverse-effects.


Subject(s)
Drug Carriers , Ivermectin , Lipids , Nanostructures , Humans , Ivermectin/administration & dosage , Ivermectin/chemistry , Ivermectin/pharmacokinetics , Ivermectin/pharmacology , Animals , Drug Carriers/chemistry , Lipids/chemistry , K562 Cells , Nanostructures/administration & dosage , Nanostructures/chemistry , Drug Synergism , Drug Liberation , Cell Survival/drug effects , Male , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Limonins/administration & dosage , Limonins/pharmacology , Limonins/chemistry , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Rats
2.
J Nanobiotechnology ; 22(1): 202, 2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38658952

ABSTRACT

Multi-modal combination therapy is regarded as a promising approach to cancer treatment. Combining chemotherapy and phototherapy is an essential multi-modal combination therapy endeavor. Ivermectin (IVM) is a potent antiparasitic agent identified as having potential antitumor properties. However, the fact that it induces protective autophagy while killing tumor cells poses a challenge to its further application. IR780 iodide (IR780) is a near-infrared (NIR) dye with outstanding photothermal therapy (PTT) and photodynamic therapy (PDT) effects. However, the hydrophobicity, instability, and low tumor uptake of IR780 limit its clinical applications. Here, we have structurally modified IR780 with hydroxychloroquine, an autophagy inhibitor, to synthesize a novel compound H780. H780 and IVM can form H780-IVM nanoparticles (H-I NPs) via self-assembly. Using hyaluronic acid (HA) to modify the H-I NPs, a novel nano-delivery system HA/H780-IVM nanoparticles (HA/H-I NPs) was synthesized for chemotherapy-phototherapy of colorectal cancer (CRC). Under NIR laser irradiation, HA/H-I NPs effectively overcame the limitations of IR780 and IVM and exhibited potent cytotoxicity. In vitro and in vivo experiment results showed that HA/H-I NPs exhibited excellent anti-CRC effects. Therefore, our study provides a novel strategy for CRC treatment that could enhance chemo-phototherapy by modulating autophagy.


Subject(s)
Autophagy , Colorectal Neoplasms , Drug Repositioning , Ivermectin , Nanoparticles , Autophagy/drug effects , Animals , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/therapy , Humans , Mice , Nanoparticles/chemistry , Ivermectin/pharmacology , Ivermectin/chemistry , Cell Line, Tumor , Indoles/chemistry , Indoles/pharmacology , Mice, Inbred BALB C , Mice, Nude , Photochemotherapy/methods , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Phototherapy/methods , Hyaluronic Acid/chemistry , Hydroxychloroquine/pharmacology , Hydroxychloroquine/chemistry , Photothermal Therapy/methods
3.
Article in English | MEDLINE | ID: mdl-32364004

ABSTRACT

The behaviour of residues of tebuconazole, prochloraz, and abamectin in rehmannia during rehmannia decoction processing was systemically assessed. The pesticides were determined by ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS) after each processing step including washing, steaming and drying, carbonising, and boiling. Results showed that the pesticide residues significantly decreased after the steps of washing, carbonising, and boiling. Washing reduced pesticide residues by 41.2%-60.0%; carbonising reduced pesticides by 27.1%-71.1% in both prepared rehmannia and unprepared rehmannia. After boiling, the concentrations of tebuconazole and prochloraz were 0.0002-0.0022 mg kg-1 in decoctions. Abamectin was not detected in rehmannia after carbonising, and it was not detected in decoctions either. The processing factors (PFs) were less than 1 during food processing, indicating that the full set of processing can reduce the residues of tebuconazole, prochloraz, and abamectin in rehmannia decoction.


Subject(s)
Food Contamination/analysis , Imidazoles/isolation & purification , Ivermectin/analogs & derivatives , Pesticide Residues/isolation & purification , Rehmannia/chemistry , Triazoles/isolation & purification , Chromatography, High Pressure Liquid , Food Handling , Imidazoles/chemistry , Ivermectin/chemistry , Ivermectin/isolation & purification , Medicine, Chinese Traditional , Pesticide Residues/chemistry , Tandem Mass Spectrometry , Triazoles/chemistry
4.
Colloids Surf B Biointerfaces ; 189: 110823, 2020 May.
Article in English | MEDLINE | ID: mdl-32036331

ABSTRACT

The aim of this work was to develop microemulsions and microemulsion gels which can be used as vehicles for the topical delivery of ivermectin. Tea tree oil and ethyl butanoate were found to be suitable for ivermectin-loaded microemulsion formulations due to the higher solubility of ivermectin in these two oils than other tested oils. The pseudo-ternary phase diagrams were constructed based on these selected oils and combination of different surfactant/co-surfactant at different ratios. Ivermectin-loaded stable microemulsions and microemulsion gels were successfully formulated based on the selected compositions from the phase diagrams. Ivermectin-loaded microemulsions showed spherical nano-droplets dispersed in the continuous phase (via cryogenic field emission scanning electron microscope image) and the particle size was less than 100 nm (via dynamic light scattering measurement). Ethyl butanoate based microemulsion appeared to be the best microemulsion formulation considering the stability and permeation profiles while tea tree oil based microemulsion showed the best stability profile. Overall, microemulsion gel formulations exhibited better stability profiles than their microemulsion counterparts. All microemulsion gel formulations demonstrated significantly faster in vitro membrane permeation (release) rate of ivermectin than Soolantra cream (reference marketed product by Galderma, USA).The developed microemulsion and microemulsion gel formulations appear to be promising vehicles for topical delivery of ivermectin.


Subject(s)
Antiparasitic Agents/chemistry , Butyrates/chemistry , Ivermectin/chemistry , Tea Tree Oil/chemistry , Drug Compounding , Drug Delivery Systems , Emulsions/chemistry , Particle Size , Solubility , Surface Properties
5.
Int J Pharm ; 556: 338-348, 2019 Feb 10.
Article in English | MEDLINE | ID: mdl-30553955

ABSTRACT

Controlled drug-delivery systems have potential as substitutes for traditional medication systems due to the advantages in safety, efficacy, and patient compliance that these long-acting dosage forms provide. In this context, the present study focus on the development of self-implanted hyaluronic acid (HA) tiny needles that encapsulate ivermectin (IVM)-poly (lactic-co-glycolic acid) (PLGA) microparticles for controlled transdermal IVM release to treat parasitic diseases. The fabricated tiny needles involved matching portable applicator have potentially able for self-administration by patients without intense pain or complexity of current controlled-release devices. The biodegradable IVM-loaded PLGA microparticles were prepared and encapsulated within the tip of dissolving HA tiny needles to achieve high delivery efficiency. The drug loading of tiny needles might be controlled by varying the repeat time of filling or pressing processes. In-vitro tests showed that the tiny needles have sufficient mechanical strength to be inserted into skin within seconds and, next rapidly dissolved to release the loaded drug carriers into subcutaneous tissues for intradermal sustained IVM release. With the in-vivo test in rats, the insertion site recovered barrier property within 3 h. In comparison to traditional hypodermic injection or implantation of controlled-release systems, the proposed polymer tiny needles can be considered as a promising device for controlled transdermal drug delivery.


Subject(s)
Antiparasitic Agents/administration & dosage , Drug Delivery Systems , Hyaluronic Acid/chemistry , Ivermectin/administration & dosage , Administration, Cutaneous , Animals , Antiparasitic Agents/chemistry , Chemistry, Pharmaceutical/methods , Delayed-Action Preparations , Drug Carriers/chemistry , Drug Liberation , Female , Ivermectin/chemistry , Mice , Needles , Polylactic Acid-Polyglycolic Acid Copolymer/chemistry , Polymers/chemistry , Rats , Rats, Sprague-Dawley , Self Administration
6.
Int J Mol Sci ; 19(11)2018 Nov 13.
Article in English | MEDLINE | ID: mdl-30428563

ABSTRACT

Lymphatic filariasis and onchocerciasis caused by filarial nematodes are important diseases leading to considerable morbidity throughout tropical countries. Diethylcarbamazine (DEC), albendazole (ALB), and ivermectin (IVM) used in massive drug administration are not highly effective in killing the long-lived adult worms, and there is demand for the development of novel macrofilaricidal drugs affecting new molecular targets. A Ca2+ binding protein, calumenin, was identified as a novel and nematode-specific drug target for filariasis, due to its involvement in fertility and cuticle development in nematodes. As sterilizing and killing effects of the adult worms are considered to be ideal profiles of new drugs, calumenin could be an eligible drug target. Indeed, the Caenorhabditis elegans mutant model of calumenin exhibited enhanced drug acceptability to both microfilaricidal drugs (ALB and IVM) even at the adult stage, proving the roles of the nematode cuticle in efficient drug entry. Molecular modeling revealed that structural features of calumenin were only conserved among nematodes (C. elegans, Brugia malayi, and Onchocerca volvulus). Structural conservation and the specificity of nematode calumenins enabled the development of drugs with good target selectivity between parasites and human hosts. Structure-based virtual screening resulted in the discovery of itraconazole (ITC), an inhibitor of sterol biosynthesis, as a nematode calumenin-targeting ligand. The inhibitory potential of ITC was tested using a nematode mutant model of calumenin.


Subject(s)
Antinematodal Agents/chemistry , Antinematodal Agents/pharmacology , Drug Discovery , Albendazole/chemistry , Albendazole/pharmacology , Albendazole/therapeutic use , Amino Acid Sequence , Animals , Antinematodal Agents/therapeutic use , Caenorhabditis elegans/drug effects , Caenorhabditis elegans/metabolism , Caenorhabditis elegans Proteins/chemistry , Caenorhabditis elegans Proteins/metabolism , Calcium-Binding Proteins/chemistry , Calcium-Binding Proteins/metabolism , Diethylcarbamazine/chemistry , Diethylcarbamazine/pharmacology , Diethylcarbamazine/therapeutic use , Drug Evaluation, Preclinical , Filariasis/drug therapy , Itraconazole/chemistry , Itraconazole/pharmacology , Itraconazole/therapeutic use , Ivermectin/chemistry , Ivermectin/pharmacology , Ivermectin/therapeutic use , Models, Molecular , Quantitative Structure-Activity Relationship
7.
Food Chem ; 268: 264-270, 2018 Dec 01.
Article in English | MEDLINE | ID: mdl-30064756

ABSTRACT

The aim of this study was to determine the insecticide residue processing factor (PF) from plums to prunes and the effect of the industrial processing of prunes residue concentrations. Our results show an increase of insecticide concentrations during plum dehydration that is explained by fruit water loss; however, the normalized insecticide residue concentration, based on plum dry weights to compensate dehydration, was reduced. The water washing and tenderizing of prunes produced insecticide residue reductions of 22.9 ±â€¯4.5% and 21.9 ±â€¯4.2%, respectively. PF were: 1.157, 1.872, 1.316, 0.192, 2.198, 0.775 and 0.156 for buprofezin, l-cyhalothrin, spirodiclofen, indoxacarb, acetamiprid, imidacloprid and emamectin benzoate, respectively, being directly related to water solubility, aqueous hydrolysis and degradation point and inversely related to molecular mass and melting point. In plums for the dehydrated agroindustry the final product is prunes, therefore, it is crucial to consider the PF to determine the specific preharvest interval for this important agroindustry.


Subject(s)
Gas Chromatography-Mass Spectrometry , Pesticide Residues/analysis , Prunus domestica/chemistry , Fruit/chemistry , Fruit/metabolism , Ivermectin/analogs & derivatives , Ivermectin/analysis , Ivermectin/chemistry , Ivermectin/isolation & purification , Neonicotinoids/analysis , Neonicotinoids/chemistry , Neonicotinoids/isolation & purification , Nitriles/analysis , Nitriles/chemistry , Nitriles/isolation & purification , Nitro Compounds/analysis , Nitro Compounds/chemistry , Nitro Compounds/isolation & purification , Oxazines/analysis , Oxazines/chemistry , Oxazines/isolation & purification , Oxidation-Reduction , Pesticide Residues/chemistry , Pesticide Residues/isolation & purification , Prunus domestica/metabolism , Pyrethrins/analysis , Pyrethrins/chemistry , Pyrethrins/isolation & purification , Solid Phase Extraction
8.
Environ Sci Pollut Res Int ; 25(16): 15909-15917, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29589235

ABSTRACT

Abamectin (ABM) is a widely utilized potent anthelmintic and insecticidal agent. In this study, we investigated the protective effects of caffeic acid phenethyl ester (CAPE) and betaine (BET) against ABM-induced hepatotoxicity and nephrotoxicity in rats. Forty rats were divided into five groups, receiving either oral saline solution (normal control), oral ABM at a dose of 2 mg/kg BW (1/5 LD50), CAPE (10 µmol/kg BW intraperitoneally) followed by ABM, or BET supplementation at a dose of 250 mg/kg BW followed by ABM administration, while group V rats received a combination of i.p. CAPE and oral BET in the same doses before receiving ABM. Biochemical analysis showed that ABM administration significantly (p < 0.05) increased serum levels of aminotransferases, alkaline phosphatase, lactate dehydrogenase, and cholesterol, as well as serum creatinine and urea. Compared to the control group, ABM-intoxicated rats had significantly (p < 0.05) higher tissue concentrations of nitric oxide and malondialdehyde, as well as lower tissue glutathione concentration, total antioxidant capacity, and antioxidant enzymatic activity (glutathione peroxidase, superoxide dismutase, and catalase). Histopathological examination of hepatic and renal tissues of ABM-intoxicated rats showed acute inflammatory and necrotic changes. Pretreatment with CAPE and/or BET reversed the biochemical and histopathological alterations of ABM on the liver and kidneys. Therefore, CAPE and BET (alone or in combination) could be promising protective agents against ABM-induced hepatotoxicity and nephrotoxicity. Future studies should confirm our findings and evaluate the other molecular effects are involved in the combination chemoprotection of CAPE and BET.


Subject(s)
Antioxidants/pharmacology , Betaine , Caffeic Acids , Chemical and Drug Induced Liver Injury/pathology , Creatinine/blood , Glutathione Peroxidase/chemistry , Glutathione/chemistry , Ivermectin/analogs & derivatives , Kidney/pathology , Malondialdehyde/chemistry , Phenylethyl Alcohol/analogs & derivatives , Superoxide Dismutase/chemistry , Animals , Betaine/pharmacology , Caffeic Acids/pharmacology , Catalase/metabolism , Chemical and Drug Induced Liver Injury/metabolism , Creatinine/chemistry , Glutathione/pharmacology , Ivermectin/chemistry , Ivermectin/metabolism , Ivermectin/toxicity , Kidney/cytology , Kidney/drug effects , Male , Malondialdehyde/pharmacology , Nitric Oxide/chemistry , Nitric Oxide/metabolism , Phenylethyl Alcohol/pharmacology , Rats , Rats, Wistar , Superoxide Dismutase/metabolism
9.
J Agric Food Chem ; 66(26): 6552-6560, 2018 Jul 05.
Article in English | MEDLINE | ID: mdl-28562041

ABSTRACT

Avermectin (AVM) is a low-toxic and high-active biopesticide, but it can be easily degraded by UV light. In this paper, biodegradable castor oil-based polyurethanes (CO-PU) are synthesized and used as carriers to fabricate a new kind of AVM/CO-PU nanoemulsion through an emulsion solvent evaporation method, and the chemical structure, colloidal property, AVM loading capacity, controlled-release behavior, foliar adhesion, and photostability of the AVM/CO-PU drug delivery systems are investigated. Results show that AVM is physically encapsulated in the CO-PU carrier nanospheres, the diameter of the AVM/CO-PU nanoparticles is <50 nm, and the AVM/CO-PU films are flat and smooth without any AVM aggregate. The drug loading capacity is up to 42.3 wt % with a high encapsulation efficiency of >85%. The release profiles indicate that the release rate is relatively high at the early stage and then slows, which can be adjusted by loaded AVM content, temperature, and pH of the release medium. The foliar pesticide retention of the AVM/CO-PU nanoemulsions is improved, and the photolysis rate of AVM in the AVM/CO-PU nanoparticles is significantly slower than that of the free AVM. A release mechanism of the AVM/CO-PU nanoemulsions is proposed, which is controlled by both diffusion and matrix erosion.


Subject(s)
Castor Oil/chemistry , Delayed-Action Preparations/chemistry , Insecticides/chemistry , Ivermectin/analogs & derivatives , Polyurethanes/chemistry , Drug Carriers/chemistry , Drug Compounding , Drug Delivery Systems , Emulsions/chemistry , Ivermectin/chemistry , Temperature
10.
Drug Deliv ; 24(1): 622-631, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28282989

ABSTRACT

This work aimed to develop a sustained release solid dispersion of ivermectin (IVM-SD) in a lipid matrix (hydrogenated castor oil, HCO) for subcutaneous delivery. Solvent-melting technology was employed to prepare IVM-SDs using HCO. The physicochemical properties of the IVM-SDs were evaluated by scanning electron microscopy (SEM), X-ray powder diffraction (XRPD), and Fourier transform infrared spectroscopy (FTIR). The release of IVM from IVM-SDs was evaluated with HPLC in vitro. Pharmacokinetics of IVM was studied in rabbits following a single subcutaneous administration of IVM-SD formulations. The efficacy of IVM-SD against the ear mange mite was evaluated in rabbits. IVM was completely dispersed in HCO in an amorphous state at a drug:carrier ratio lower than 1:3. No chemical interactions between drug and carrier were found besides hydrogen bonding for the amorphous IVM-SDs. The amorphous IVM-SDs formulations exhibited a sustained release of IVM versus physical mixtures (PMs) of IVM and HCO. The drug release decreased as the drug:carrier ratios decreased, and the release kinetics of IVM were controlled via diffusion. Cytotoxicity of IVM-SD to MDCK cells was lower than native IVM. The IVM plasma concentration of SD1:3 remained above 1 ng/mL for 49 d. Higher AUC, MRT, and Tmax values were obtained at a SD1:3 relative to the IVM group. The IVM-SD improved almost 1.1-fold bioavailability of drug compared with IVM in rabbits. IVM-SD could provide longer persistence against rabbit's ear mites than a commercial IVM injection. This study shows that these solid lipid dispersions are a promising approach for the development of subcutaneous IVM formulations.


Subject(s)
Antiparasitic Agents/administration & dosage , Castor Oil/chemistry , Drug Carriers , Ivermectin/administration & dosage , Mite Infestations/veterinary , Psoroptidae/drug effects , Animals , Antiparasitic Agents/chemistry , Antiparasitic Agents/pharmacokinetics , Antiparasitic Agents/toxicity , Biological Availability , Castor Oil/analogs & derivatives , Castor Oil/toxicity , Cell Survival/drug effects , Chromatography, High Pressure Liquid , Crystallography, X-Ray , Delayed-Action Preparations , Dogs , Drug Compounding , Hydrogenation , Injections, Subcutaneous , Ivermectin/chemistry , Ivermectin/pharmacokinetics , Ivermectin/toxicity , Madin Darby Canine Kidney Cells , Male , Microscopy, Electron, Scanning , Mite Infestations/drug therapy , Mite Infestations/parasitology , Powder Diffraction , Rabbits , Solubility , Spectroscopy, Fourier Transform Infrared , Technology, Pharmaceutical/methods
11.
Trop Anim Health Prod ; 49(1): 55-61, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27718107

ABSTRACT

Forty-five Pelibuey sheep were experimentally infested with nematodes to evaluate the effect of three free condensed tannin (FCT) levels of Lysiloma acapulcensis on fecal egg counts (FECs), packed cell volumes (PCV), ocular mucosa colors (OMC), average daily gain (ADG), and adult nematode count. Five treatments were used: 12.5, 25.0, and 37.5 mg of FCT kg-1 of body weight (BW); sterile water (control); and ivermectine (0.22 mg kg-1 of BW) as chemical group. The data were processed through repeated measurement analysis. Even though the three FCT doses decreased (P < 0.05) the FEC, the highest reduction was obtained with 37.5 mg kg-1 of BW. No differences were observed in PCV and OMC. Higher ADG (P < 0.05) was observed with 37.5 mg kg-1 of BW of FCT. The count of adult nematodes (females and males) in the higher dose of FCT was similar to chemical treatment. Dose of 37.5 mg kg-1 of BW decreased the parasite infection and improved the lamb performance. Therefore, this dose could be used as a nutraceutic product in sheep production.


Subject(s)
Haemonchiasis/veterinary , Parasite Egg Count/veterinary , Proanthocyanidins/therapeutic use , Sheep Diseases/drug therapy , Animals , Body Weight , Dietary Supplements , Fabaceae/chemistry , Feces/parasitology , Female , Haemonchiasis/drug therapy , Hematocrit/veterinary , Ivermectin/chemistry , Male , Mucous Membrane , Nematoda , Sheep , Sheep Diseases/parasitology , Sheep, Domestic , Tannins/chemistry , Weight Gain
13.
Biol Pharm Bull ; 34(10): 1619-23, 2011.
Article in English | MEDLINE | ID: mdl-21963505

ABSTRACT

Microbial samples, including our library of known microbial compounds (ca. 300) and microbial culture broths (ca. 9000), were screened for small molecules affecting the phenotype of Caenorhabditis elegans. As a result, seven known compounds were found to induce phenotypic abnormality of C. elegans. Staurosporine exhibited morphological defects in the vulva and tail of C. elegans, avermectin B1a exhibited hatching inhibition of starting eggs on day 1 at 25-100 µM and growth inhibition at 0.01-12.5 µM, siccanin and antimycin A inhibited the growth of C. elegans, and fluorouracil inhibited hatching of eggs newly spawned by adult C. elegans. Toromycin induced morphological defects in the intestine. 5-(4-Methoxyphenyl)-oxazole, isolated as a fungal metabolite for the first time, inhibited the hatching of eggs newly spawned by adult C. elegans.


Subject(s)
Antinematodal Agents/pharmacology , Caenorhabditis elegans/drug effects , Zygote/physiology , Animals , Antinematodal Agents/chemistry , Antinematodal Agents/metabolism , Caenorhabditis elegans/genetics , Caenorhabditis elegans/growth & development , Caenorhabditis elegans/metabolism , Caenorhabditis elegans Proteins/genetics , Caenorhabditis elegans Proteins/metabolism , Drug Evaluation, Preclinical , Embryonic Development/genetics , Embryonic Development/physiology , Female , Fluorouracil/chemistry , Fluorouracil/metabolism , Fluorouracil/pharmacology , Ivermectin/analogs & derivatives , Ivermectin/chemistry , Ivermectin/metabolism , Ivermectin/pharmacology , Models, Animal , Mutation , Phenotype , Small Molecule Libraries/analysis , Small Molecule Libraries/metabolism , Tail/anatomy & histology , Vulva/anatomy & histology , Zygote/metabolism , Zygote/pathology
14.
Physiol Res ; 57 Suppl 3: S23-S38, 2008.
Article in English | MEDLINE | ID: mdl-18481917

ABSTRACT

Purinergic P2X receptors represent a novel structural type of ligand-gated ion channels activated by extracellular ATP. So far, seven P2X receptor subunits have been found in excitable as well as non-excitable tissues. Little is known about their structure, mechanism of channel opening, localization, and role in the central nervous system. The aim of this work is to summarize recent investigations and describe our contribution to elucidating the structure of the ATP binding site and transmembrane domains of the P2X receptor, we also discuss the expression and physiological roles played by the ATP and P2X receptors in the anterior pituitary and hypothalamus.


Subject(s)
Hypothalamus/metabolism , Pituitary Gland/metabolism , Receptors, Purinergic P2/chemistry , Receptors, Purinergic P2/metabolism , Adenosine Triphosphate/metabolism , Animals , Gonadotrophs/metabolism , Humans , Ivermectin/chemistry , Ivermectin/pharmacology , Models, Molecular , Neuroglia/metabolism , Neurons/metabolism , Protein Binding , Protein Structure, Quaternary , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, Purinergic P2/drug effects
15.
Trends Parasitol ; 22(2): 51-4, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16406332

ABSTRACT

Nature frequently unleashes a barrage of new and frightening diseases against humans--such as HIV, severe acquired respiratory syndrome, Ebola virus and avian flu recently--in addition to the seemingly ever-present scourges such as malaria and tuberculosis. Fortunately, nature also provides the wherewithal to help conquer the diseases that it sets loose. All that is needed is the human ingenuity to discover, develop and apply the solutions in an optimal fashion. Participants at the 9th Max Tishler Memorial Symposium (Tokyo, July 2005) were told about several new advances in the search for new anti-infective drugs derived from natural sources and were able to learn how one of the most effective drugs ever, ivermectin, made its way through what was, at the time, uncharted territory and how precedents were set at nearly every stage to form a model for all subsequent public-private partnerships.


Subject(s)
Biological Products/isolation & purification , Biological Products/therapeutic use , Naturopathy/trends , Animals , Antiparasitic Agents/chemistry , Antiparasitic Agents/isolation & purification , Antiparasitic Agents/therapeutic use , Biological Products/chemistry , Humans , Ivermectin/chemistry , Ivermectin/isolation & purification , Ivermectin/therapeutic use , Parasitic Diseases/drug therapy
16.
Bioorg Med Chem Lett ; 14(16): 4135-9, 2004 Aug 16.
Article in English | MEDLINE | ID: mdl-15261257

ABSTRACT

Novel 4"-alkoxy avermectin derivatives were synthesized via rhodium carbenoid mediated O-H insertion reaction and tested for antiparasite activity against Artemia salina and Caenorhabditis elegans.


Subject(s)
Ivermectin/analogs & derivatives , Ivermectin/chemistry , Animals , Caenorhabditis elegans/drug effects , Crustacea/drug effects , Drug Evaluation, Preclinical , Ivermectin/chemical synthesis , Ivermectin/pharmacology
17.
Eur J Pharmacol ; 493(1-3): 57-64, 2004 Jun 16.
Article in English | MEDLINE | ID: mdl-15189764

ABSTRACT

The modification of the sensitivity of Hep-2 and P388 tumor cells to taxol and vincristine, substrates of multidrug resistance proteins, by naturally occurring avermectins and the effect of avermectins on the accumulation of calcein in cells and the efflux of rhodamine 123 were studied. While avermectins did not affect the sensitivity of tumor cells to hydrogen peroxide and cisplatin, they significantly enhanced the sensitivity of cells of both wild-type and resistant strains to taxol and vincristine. The coefficients of modification for resistant strains were substantially higher. Avermectins suppressed the efflux of rhodamine 123 from cells and increased the accumulation of calcein in cells. The relative inhibitory activity of avermectins depended on the cell type and on the substrate of multidrug resistance proteins whose transport they suppressed (vincristine, taxol, rhodamine 123, calcein acetoxymethyl ester). The least active was avermectin B1 or ivermectin; the most active avermectins varied depending on the substrate and the cell type. In the case of vincristine transport, the most active avermectin was almost by one order of magnitude more effective than the traditional inhibitor of multidrug resistance cyclosporin A. This property of avermectins can be used in tumor therapy by combining application of avermectins with antitumor preparations, the substrates of multidrug resistance proteins.


Subject(s)
Cell Line, Tumor , Drug Resistance, Multiple/drug effects , Drug Resistance, Multiple/physiology , Ivermectin/analogs & derivatives , Ivermectin/pharmacology , Animals , Cell Division/drug effects , Cell Survival/drug effects , Cyclosporine/pharmacology , Dose-Response Relationship, Drug , Drug Combinations , Drug Evaluation, Preclinical/methods , Drug Synergism , Fluoresceins/metabolism , Fluorescence , Humans , Ivermectin/chemistry , Leukemia P388/pathology , Male , Mice , Paclitaxel/pharmacology , Rhodamine 123/metabolism , Rhodamine 123/pharmacology , Russia , Vincristine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL